摘要
目的探讨前列腺增生组织中T淋巴细胞亚群CD4+、CD8+的表达差异及其临床意义。方法利用免疫组织化学技术分另4检测CD4+、CD8+在人前列腺增生组织中的表达。应用计算机图像分析系统测量CD4+、CD8+表达阳性区域平均光密度值(MOD),并采用SPSS13.0对前列腺增生组织中CD4+、CD8+的MOD差异进行统计学分析。结果前列腺增生组织中CD4+、CD8+的表达较非增生的前列腺组织明显增高,且CD4+/CD8+比值明显下降(P〈0.05)。前列腺增生非结节区域CD4+的表达高于结节区,而CD8+表达低于结节区;结节区CD4+/CD8+比值较非结节区明显降低(P〈0.05)。炎症组前列腺增生结节直径〉5mm组的CD4+、CD8+表达高于结节直径≤5mm组,而CD4+/CD8+比值明显下降(P〈0.05)。结论BPH组织中的CD4+、CD8+的变化与BPH增生结节的形成、发生、发展可能有密切关系,免疫因素可能在BPH发生发展过程中起着重要的作用。
Objective o investigate the dsitribution ofCD4+ and CD8+ T lymphocyte subpopulations in prostatic hyperplasia tissue and its clinical significance. Methods The expressions of CD4 and CD8 in prostatic hyperplasia tissues were individually detected by immunohistochemical analysis. The mean optical density (MOD) of the CD4 + and CD8+ areas in prostatic hyperplasia tissue was measured by a computer image analysis system, and the difference in MOD was statistically analyzed using the SPSS 13.0 software. Results The expression levels of CD4+ and CD8+ were significantly higher in hyperplastic prostate tissue than those in non-hyperplastic prostate tissue, and the CD4 +/CD8+ ratio was significantly decreased (P〈0.05). The expression of CD4+ in the non-nodular area of prostatic hyperplasia was higher than that in the nodular area, whereas the expression of CD8 + was lower than that in the nodular area. The CD4+/ CD8+ ratio in the nodule area was significantly decreased compared as that in the non-nodular area (P〈0.05). The expression levels of CD4+ and CD8+ in the inflammatory prostatic hyperplasia group with a nodule diameter 〉5 mm were higher than those in the group with a nodule diameter ~〈5 ram, whereas the CD4+/CD8+ ratio was significantly decreased (P〈0.05). Conclusion In benign prostatic hyperplasia (BPH) tissue, CD4+ and CD8+ expressions might be closely related to occurrence and development of BPH nodules which indicated that immune factors might play an important role in the progress of BPH.
出处
《中国男科学杂志》
CAS
CSCD
北大核心
2012年第11期20-24,共5页
Chinese Journal of Andrology
基金
湖南省卫生厅科研基金(B2011-031)